Amylin analogue
Cagrilintide
Cagrilintide's half-life was 159 to 195 hours in a phase 1b trial with semaglutide 2.4 mg, and the app lists 180 hours, about 7.5 days.1
Cagrilintide after one dose: 50% at ~180 h, 25% at 360 h, 12.5% at 540 h.
Drawn from the half-life in the app's model, ~180 h. The model's figures
- Compound
- Cagrilintide
- Symbol
- CAG
- Family
- GLP-1 and incretin
- Parts
- 13
- References
- 15
- Checked
- Last reviewed . Sources are listed below.
Overview
Cagrilintide is a long-acting amylin analogue; the phase 2 authors describe natural amylin as "a pancreatic hormone that induces satiety".2 Its design was reported by Kruse and colleagues at Novo Nordisk in the Journal of Medicinal Chemistry in 2021, as "the stable, lipidated long-acting amylin analogue cagrilintide", chosen for clinical development with obesity as the indication.3
A 2026 paper describes cagrilintide as "under development as monotherapy for weight management and as a fixed-dose combination with the glucagon-like peptide-1 receptor agonist semaglutide (CagriSema)".4 The app grades the evidence for cagrilintide as emerging. The phase 1b, phase 2, type 2 diabetes phase 2, REDEFINE 1, REDEFINE 2 and kidney and liver studies described below were each funded by Novo Nordisk.1,2,5,6,7,4 The two large phase 3a trials, REDEFINE 1 and REDEFINE 2, tested cagrilintide 2.4 mg together with semaglutide 2.4 mg, so their headline results describe the combination and not cagrilintide alone.6,7
How it works
Sources in this part
Natural amylin is described by Lau and colleagues as "a pancreatic hormone that induces satiety", and cagrilintide is the long-acting analogue of it.2 In a mouse study by Carvas and colleagues (eBioMedicine, 2025), cagrilintide and salmon calcitonin were called "dual amylin-calcitonin receptor agonists", and the authors concluded that "these results demonstrate the dependency of cagrilintide on AMY1R and AMY3R to lower body weight".8 That receptor result comes from male wild-type and knockout mice fed a high-fat diet, and it is not a result in people.8 Three of its authors are full-time Novo Nordisk employees with minor shares; the paper states that they "had a consulting role in the study design, interpretation of the data and approved the final version of the manuscript" and that "Novo Nordisk had no role in the data collection or data analyses".8
Half-life and pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~180 h
- Bioavailability
- 85%
- Typical dose
- 0.3–2.4 mg/week
- Route
- SubQ
- Time to peak
- ~24 h
Sources in this part
The second column of the table holds the app's own figures, shown beside what the sources report.
| Parameter | App's figure | Reported in the sources |
|---|---|---|
| Half-life | About 7.5 days (180 hours) | 159 to 195 hours across cagrilintide 0.16 to 4.5 mg given with semaglutide 2.4 mg in the phase 1b trial; geometric mean terminal half-lives of 186, 194, 204 and 211 hours across normal, mild, moderate and severe renal function after a single 0.6 mg dose, and 174, 176, 188 and 199 hours across the hepatic function groups after a single 0.9 mg dose1,4 |
| Time to peak | About 24 hours | Median time to maximum concentration of 24 to 72 hours across cagrilintide doses in the phase 1b trial; group medians of 72, 48, 48 and 60 hours (renal groups) and 45, 36, 84 and 45 hours (hepatic groups) after single doses1,4 |
| Bioavailability | 85% by subcutaneous injection | The phase 1b trial reports exposure (Cmax 6.14 to 170 nmol/L across 0.16 to 4.5 mg) and says exposure "was proportional to cagrilintide dose"; none of the records read gives an absolute bioavailability figure, although the registry entry for the liver study lists assessing the absolute bioavailability of subcutaneous cagrilintide in healthy volunteers in its official title1,14 |
| Route | Subcutaneous | Subcutaneous self-injection of cagrilintide alone, once weekly, in the phase 2 trial2 |
The half-life figures in the phase 1b trial were exploratory endpoints measured with semaglutide 2.4 mg co-administered, so they are not a cagrilintide-alone measurement.1 The kidney and liver paper states that "the pharmacokinetics of cagrilintide are dose-proportional and linear".4
Level over 6 weeks
Level, as a share of the peak after one 100 mg dose
As studied: once weekly, as dosed in the phase 2 trial2.
An illustration from a pharmacokinetic model using a half-life of 180 hours (7.5 days). It is not a measured level or a suggested dose.
Human studies
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Enebo and colleagues, phase 1b, Lancet 20211 | Randomised, placebo-controlled, multiple-ascending-dose; funded by Novo Nordisk | 96 randomised, aged 18 to 55, BMI 27.0 to 39.9, one US centre | Cagrilintide 0.16 to 4.5 mg weekly with semaglutide 2.4 mg; 16 weeks escalation, 4 at target, 5 follow-up | Half-life 159 to 195 h; week 20 weight reduction 15.7%, 17.1% and 15.4% at 1.2, 2.4 and 4.5 mg versus 9.8% and 8.0% on placebo, all with semaglutide; adverse events in 97% versus 96% |
| Lau and colleagues, phase 2, Lancet 20212 | Randomised, double-blind, placebo- and liraglutide-controlled; funded by Novo Nordisk | 706 adults without diabetes, BMI at least 30 or at least 27 with hypertension or dyslipidaemia | Cagrilintide 0.3, 0.6, 1.2, 2.4 or 4.5 mg weekly, liraglutide 3.0 mg daily or placebo; 26 weeks | Weight reductions of 6.0% to 10.8% versus 3.0% on placebo (trial product estimand); 10.8% versus 9.0% for 4.5 mg versus liraglutide; gastrointestinal events 41% to 63% versus 32%; permanent discontinuation 10% |
| Frias and colleagues, phase 2 in type 2 diabetes, Lancet 20235 | Randomised, double-blind, active-controlled trial at 17 US sites; funded by Novo Nordisk | 92 adults with type 2 diabetes and BMI of 27 or higher on metformin with or without an SGLT2 inhibitor; mean age 58 | CagriSema (n=31), semaglutide (n=31) or cagrilintide (n=30), each escalated to 2.4 mg weekly; 32 weeks | HbA1c change of -2.2, -1.8 and -0.9 percentage points; weight change of -15.6%, -5.1% and -8.1%; CagriSema differed from cagrilintide but not from semaglutide on HbA1c |
| Garvey and colleagues, REDEFINE 1, N Engl J Med 20256 | Phase 3a, double-blind, placebo- and active-controlled; funded by Novo Nordisk | 3417 adults without diabetes, BMI 30 or higher, or 27 or higher with an obesity-related complication | Cagrilintide 2.4 mg with semaglutide 2.4 mg, each alone, or placebo, assigned 21:3:3:7, plus lifestyle intervention; 68 weeks | Weight change of -20.4% with the combination versus -3.0% with placebo (treatment-policy estimand); gastrointestinal events 79.6% versus 39.9% |
| Davies and colleagues, REDEFINE 2, N Engl J Med 20257 | Phase 3a, double-blind, placebo-controlled trial in 12 countries; funded by Novo Nordisk | 1206 adults with type 2 diabetes, BMI 27 or more, HbA1c 7 to 10% | Cagrilintide 2.4 mg with semaglutide 2.4 mg (n=904) or placebo (n=302), plus lifestyle intervention; 68 weeks | Weight change of -13.7% versus -3.4% (treatment-policy estimand); HbA1c of 6.5% or less in 73.5% versus 15.9%; gastrointestinal events 72.5% versus 34.4% |
| Nielsen and colleagues, kidney and liver studies, Clin Pharmacokinet 20264 | Two phase 1 single-dose studies; funded by Novo Nordisk | 33 adults grouped by kidney function, 32 by liver function | Single cagrilintide 0.6 mg (kidney) or 0.9 mg (liver); follow-up to day 36 or 39 | AUC ratios versus normal function 1.18 to 1.23 (kidney, 90% CIs 0.87 to 1.68) and 0.99 to 1.11 (liver, 90% CIs 0.89 to 1.30); no serious adverse events or deaths |
Deeper analysis: phase 1b trial with semaglutide (Enebo and colleagues, Lancet 2021)
Enebo and colleagues ran a single-centre, randomised, placebo-controlled, multiple-ascending-dose trial with six sequential overlapping cohorts, randomising 3:1 to once-weekly cagrilintide or matched placebo, always with semaglutide 2.4 mg and without lifestyle interventions.1 The primary endpoint was the number of treatment-emergent adverse events.1 There were 566 adverse events in 92 participants (97% of those on cagrilintide and 96% of those on placebo), of which 207 (37%) were gastrointestinal, and the authors report that "Most adverse events were mild to moderate in severity".1 Weight reductions at week 20 were greater with cagrilintide 1.2 and 2.4 mg than pooled placebo (estimated differences -6.0% and -7.4%) and with 4.5 mg than matched placebo (-7.4%), all with semaglutide 2.4 mg, so the result describes the combination.1 The authors also report that "Glycaemic parameters improved in all treatment groups, independently of cagrilintide dose".1 Their own caution is that "Future larger and longer trials are needed to fully assess the efficacy and safety of this treatment combination", and the weight results were exploratory pharmacodynamic endpoints.1 The sponsor was Novo Nordisk A/S; four authors are described as "employees and shareholders at Novo Nordisk A/S", the principal investigator "received sponsorship from Novo Nordisk", and one author is a Novo Nordisk consultant and shareholder.1 The registry lists the trial as completed.9
Deeper analysis: phase 2 dose-finding trial (Lau and colleagues, Lancet 2021)
Lau and colleagues enrolled adults aged at least 18 years without diabetes at 57 sites in ten countries and randomised them 6:1 to weekly cagrilintide, daily liraglutide 3.0 mg or volume-matched placebo.2 The primary endpoint was percentage change in bodyweight to week 26, analysed under a trial product estimand (assuming adherence) and a treatment policy estimand (regardless of adherence), and masking held for active versus placebo but not between different active treatments.2 Under the trial product estimand, weight fell by 6.0% to 10.8% across cagrilintide doses versus 3.0% on placebo, and the authors report that "Similar weight loss reductions were observed with the treatment policy estimand".2 For the 4.5 mg dose against liraglutide 3.0 mg, weight fell by 10.8% versus 9.0% (estimated treatment difference 1.8%, p=0.03).2 Permanent discontinuation occurred in 73 participants (10%), mostly because of adverse events (30, 4%), and 29 participants (4%) withdrew from the trial.2 Gastrointestinal events were reported by 41% to 63% on cagrilintide versus 32% on placebo, primarily nausea (20% to 47% versus 18%).2 The registry results list no deaths in any arm and serious adverse events in 6, 2, 7, 3 and 4 participants at 0.3, 0.6, 1.2, 2.4 and 4.5 mg, 4 on liraglutide and 3 on placebo.10 The authors conclude that cagrilintide "led to significant reductions in bodyweight and was well tolerated".2 The PubMed record read for this trial does not include a limitations passage, so the authors' stated limitations are not reported here.2 The trial was funded by Novo Nordisk A/S, three authors are "employees and shareholders at Novo Nordisk A/S", one is a Novo Nordisk consultant and shareholder, and the lead author has received research funding from Novo Nordisk.2
Deeper analysis: phase 2 in type 2 diabetes (Frias and colleagues, Lancet 2023)
Frias and colleagues randomised 92 US adults with type 2 diabetes 1:1:1 to CagriSema, semaglutide or cagrilintide, each escalated to 2.4 mg, with change in HbA1c from baseline to week 32 as the primary endpoint.5 HbA1c fell by 2.2, 1.8 and 0.9 percentage points; CagriSema was lower than cagrilintide (difference -1.3 percentage points, 95% CI -1.7 to -0.8) but not than semaglutide (-0.4, 95% CI -0.8 to 0.0; p=0.075).5 The cagrilintide-alone arm (n=30) lost 8.1% of body weight and its fasting plasma glucose fell by 1.7 mmol/L, against 15.6% and 3.3 mmol/L with CagriSema.5 Adverse events were reported by 21 (68%), 22 (71%) and 24 (80%) participants in the CagriSema, semaglutide and cagrilintide groups, "Mild or moderate gastrointestinal adverse events were most common", no level 2 or 3 hypoglycaemia was reported and no fatal adverse events were reported.5 The authors say the data "support further investigation of CagriSema in this population in longer and larger phase 3 studies".5 The trial was funded by Novo Nordisk, and the declarations state that "SD, LE, and SM are employed at Novo Nordisk and are stockholders of Novo Nordisk shares".5
Deeper analysis: REDEFINE 1 (Garvey and colleagues, New England Journal of Medicine 2025)
REDEFINE 1 randomised 3417 adults 21:3:3:7 to the combination, semaglutide 2.4 mg alone, cagrilintide 2.4 mg alone or placebo (2108, 302, 302 and 705 participants), all with lifestyle interventions.6 The coprimary endpoints compared the combination with placebo, and effects were estimated with the treatment-policy estimand "consistent with the intention-to-treat principle".6 Weight changed by -20.4% with the combination versus -3.0% with placebo (estimated difference -17.3 percentage points, 95% CI -18.1 to -16.6), and the combination reached the weight-loss targets of 5% or more, 20% or more, 25% or more and 30% or more more often than placebo.6 The PubMed record gives no result for the cagrilintide-alone or semaglutide-alone arms, so the contribution of cagrilintide on its own is not stated there.6 Gastrointestinal events affected 79.6% on the combination and 39.9% on placebo, "mainly transient and mild-to-moderate in severity".6 Novo Nordisk's December 2025 press release, a company statement and not a peer-reviewed source, reports discontinuation for adverse events of 5.9% on CagriSema versus 3.5% on placebo, with nausea in 55% versus 12.6%, constipation in 30.7% versus 11.6% and vomiting in 26.1% versus 4.1%.12 The registry lists Novo Nordisk A/S as lead sponsor and the status "ACTIVE_NOT_RECRUITING".11 The authors state "Funded by Novo Nordisk", and the author list places three authors (Osorto Contreras, Winning Lehmann and Zeuthen) at Novo Nordisk, Søborg.6 The PubMed record read gives neither the authors' limitations nor individual declarations of interest.6
Deeper analysis: REDEFINE 2 (Davies and colleagues, New England Journal of Medicine 2025)
Davies and colleagues assigned 1206 adults with type 2 diabetes, a BMI of 27 or more and HbA1c of 7 to 10% 3:1 to cagrilintide-semaglutide (904) or placebo (302) for 68 weeks, in 12 countries.7 The two primary endpoints were percent change in body weight and the percentage with a weight reduction of at least 5%.7 Weight changed by -13.7% versus -3.4% (estimated difference -10.4 percentage points, 95% CI -11.2 to -9.5), and an HbA1c of 6.5% or less was reached by 73.5% versus 15.9%.7 Gastrointestinal events were reported by 72.5% versus 34.4%, "most of which were transient and mild or moderate in severity".7 The company release gives discontinuation for adverse events of 8.4% on CagriSema versus 3% on placebo in this trial.12 The registry lists the trial as completed with Novo Nordisk A/S as lead sponsor, and the authors state "Funded by Novo Nordisk", with three authors (Broholm, Eliasen and Lyndgaard) at Novo Nordisk, Søborg.13,7 The PubMed record read does not include the authors' limitations or individual declarations of interest.7
Deeper analysis: kidney and liver studies (Nielsen and colleagues, Clinical Pharmacokinetics 2026)
Two phase 1 studies gave a single dose of cagrilintide 0.6 mg (kidney study, 33 participants) or 0.9 mg (liver study, 32 participants) to adults grouped by normal function and mild, moderate or severe impairment, with AUC from time zero to infinity as the primary endpoint.4 Exposure ratios against normal function ranged from 1.18 to 1.23 in the kidney groups (90% CIs spanning 0.87 to 1.68) and 0.99 to 1.11 in the liver groups (90% CIs spanning 0.89 to 1.30).4 The authors note a tendency toward longer half-life with greater impairment, which "was not considered clinically relevant, as exposure was similar between groups".4 There were 21 and 16 treatment-emergent adverse events in 11 and 9 participants, with no serious events, withdrawals or deaths, and the most frequent events were "nausea, vomiting, decreased appetite and injection site erythema".4 The authors list as limitations "the use of a single dose rather than multiple doses of cagrilintide" and doses "lower than the 2.4 mg dose being evaluated in clinical development", and add that "both studies had low numbers of participants, with the fewest in the groups with severe renal or hepatic impairment".4 Both studies were funded by Novo Nordisk A/S, the lead author is affiliated with Novo Nordisk, and the registry lists the liver study as completed.4,14
Doses reported in studies and on labels
No product label for cagrilintide was identified in DailyMed.12
| Study | Cagrilintide dose and schedule (subcutaneous) | Comparator and participants | Length |
|---|---|---|---|
| Phase 1b, Enebo 20211 | 0.16, 0.30, 0.60, 1.2, 2.4 or 4.5 mg weekly with semaglutide 2.4 mg, co-escalated in 4-week intervals | Matched placebo with semaglutide; 96 randomised | 16 weeks escalation, 4 weeks at target, 5 weeks follow-up |
| Phase 2, Lau 20212,10 | 0.3, 0.6, 1.2, 2.4 or 4.5 mg weekly; for 2.4 mg, 0.6 mg at week 0, 1.2 mg at week 2, 2.4 mg from week 4 | Liraglutide 3.0 mg daily or placebo; 706 randomised | 26 weeks plus 6 weeks follow-up |
| Phase 2 in type 2 diabetes, Frias 20235 | Escalated to 2.4 mg weekly, alone (n=30) | CagriSema (n=31) or semaglutide (n=31); 92 randomised | 32 weeks |
| REDEFINE 1, Garvey 20256 | 2.4 mg weekly with semaglutide 2.4 mg, or 2.4 mg alone | Semaglutide 2.4 mg alone or placebo; 3417 randomised; treatment-policy estimand | 68 weeks |
| REDEFINE 2, Davies 20257 | 2.4 mg weekly with semaglutide 2.4 mg | Placebo; 1206 randomised; treatment-policy estimand | 68 weeks |
| Kidney study, Nielsen 20264 | Single 0.6 mg dose | Normal function (n=14) versus mild, moderate, severe impairment (n=7, 7, 5) | Single dose, follow-up to day 36 |
| Liver study, Nielsen 20264 | Single 0.9 mg dose | Normal function (n=14) versus mild, moderate, severe impairment (n=7, 7, 4) | Single dose, follow-up to day 39 |
Side effects reported
Sources in this part
Gastrointestinal events were the most frequent adverse events in the phase 2 trial, which listed "nausea, constipation, and diarrhoea" and "administration-site reactions".2 In REDEFINE 1 and REDEFINE 2, gastrointestinal events affected 79.6% versus 39.9% and 72.5% versus 34.4% of people on the combination versus placebo.6,7 Rates of adverse events with the combination cannot be read as rates for cagrilintide alone, and the cagrilintide-alone arms were smaller (30 in the type 2 diabetes trial, 302 in REDEFINE 1).5,6
Bloodwork and markers
Sources in this part
The app lists HbA1c, fasting glucose and heart rate as markers to monitor. HbA1c and fasting plasma glucose were measured in the type 2 diabetes phase 2 trial, where the cagrilintide-alone arm had HbA1c changes of -0.9 percentage points and fasting plasma glucose changes of -1.7 mmol/L.5 In REDEFINE 2, an HbA1c of 6.5% or less was reached by 73.5% on the combination and 15.9% on placebo.7 In the phase 1b trial, glycaemic parameters "improved in all treatment groups, independently of cagrilintide dose", with semaglutide co-administered.1 The phase 2 registry results report change in pulse from week 0 to week 26 of -2.1, -0.6, -1.2, -2.0 and -4.5 beats per minute at cagrilintide 0.3, 0.6, 1.2, 2.4 and 4.5 mg, against +1.6 with liraglutide 3.0 mg and -0.1 with pooled placebo (means, as posted).10
Regulatory and anti-doping status
Sources in this part
Novo Nordisk announced on 18 December 2025 the submission of a New Drug Application to the US Food and Drug Administration for once-weekly CagriSema (cagrilintide 2.4 mg and semaglutide 2.4 mg), and stated that "CagriSema is not approved in the US or EU".12 The release adds that "The FDA is expected to review the CagriSema application in 2026"; the outcome of that review is not covered by the records read.12 In the 2026 World Anti-Doping Agency Prohibited List, class S0 is "PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION)" and covers a pharmacological substance not addressed in later sections "with no current approval by any governmental regulatory health authority for human therapeutic use" and gives "drugs under pre-clinical or clinical development" as an example.15 The 2026 list text read does not name cagrilintide or amylin analogues; the examples it gives for S0 include BPC-157 and 2,4-dinitrophenol, and the 2027 list was not read.15
What is not known
Sources in this part
No label or regulator assessment for cagrilintide as a single product was identified, and cagrilintide-alone efficacy in the records read comes from the 26-week phase 2 trial (about 100 per dose group) and the 30-person arm of the 32-week type 2 diabetes trial; REDEFINE 1 also had a 302-person cagrilintide 2.4 mg arm, whose result is not in the record read.2,5,6 The phase 1b half-life range was measured with semaglutide co-administered, and no absolute bioavailability figure was identified in the records read, so the app's 85% stands without a published figure beside it.1 For the phase 1b, phase 2, type 2 diabetes phase 2, REDEFINE 1 and REDEFINE 2 trials, the records read were the PubMed records, because the full texts were not in PubMed Central, so secondary endpoints, subgroup results and several authors' limitations sections are not covered here.2,6 The longest treatment period in the records read is 68 weeks (REDEFINE 1 and 2), so longer exposure is not described.6
Frequently asked questions
What is the half-life of cagrilintide?
What is cagrilintide?
How long does cagrilintide take to reach its peak level?
The phase 1b trial reported a median time to maximum concentration of 24 to 72 hours, and the app lists about 24 hours.1
Is cagrilintide approved?
Is cagrilintide banned by WADA?
What is CagriSema?
CagriSema is a fixed-dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg.12
What weight change was reported in the cagrilintide phase 2 trial?
Does kidney or liver impairment change cagrilintide exposure?
In single-dose studies, AUC ratios against normal function were 1.18 to 1.23 in kidney groups (90% CIs 0.87 to 1.68) and 0.99 to 1.11 in liver groups (90% CIs 0.89 to 1.30), and the authors describe low participant numbers.4
Guides, tools and comparisons
References
- Enebo LB, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial. Lancet 2021. PMID 33894838
- Lau DCW, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet 2021. PMID 34798060
- Kruse T, et al. Development of Cagrilintide, a Long-Acting Amylin Analogue. J Med Chem 2021. PMID 34288673
- Nielsen MJF, et al. Renal or Hepatic Impairment Does Not Affect Pharmacokinetics, Safety, or Tolerability of Subcutaneous Cagrilintide. Clin Pharmacokinet 2026. PMC13356073
- Frias JP, et al. Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. Lancet 2023. PMID 37364590
- Garvey WT, et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. N Engl J Med 2025. PMID 40544433
- Davies MJ, et al. Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. N Engl J Med 2025. PMID 40544432
- Carvas AO, et al. Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3. eBioMedicine 2025. PMC12270663
- ClinicalTrials.gov. NCT03600480, phase 1b cagrilintide with semaglutide. Sponsor Novo Nordisk A/S. NCT03600480
- ClinicalTrials.gov. NCT03856047, phase 2 cagrilintide dose-finding. Sponsor Novo Nordisk A/S. NCT03856047
- ClinicalTrials.gov. NCT05567796, REDEFINE 1. Sponsor Novo Nordisk A/S. NCT05567796
- Novo Nordisk. Novo Nordisk files for FDA approval of CagriSema. Press release, 18 December 2025, as posted on BioSpace. Novo Nordisk press release
- ClinicalTrials.gov. NCT05394519, REDEFINE 2. Sponsor Novo Nordisk A/S. NCT05394519
- ClinicalTrials.gov. NCT05564104, single-dose cagrilintide in hepatic impairment. Sponsor Novo Nordisk A/S. NCT05564104
- World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list